Important Safety Information

Consult the Product Monograph at [PM link placeholder] for important information about:

• Contraindications in patients who are hypersensitive to somatostatin or related peptides and patients with complicated untreated lithiasis of the bile ducts
• The most serious warnings and precautions are regarding loss of blood glucose control (hypoglycemia in diabetic patients; hyperglycemia); the potential for the reduction of gallbladder motility that may lead to gallstone formation; drug interaction with cyclosporine
• Other relevant warnings and precautions regarding cardiovascular disorders; driving or operating heavy machinery; hypoglycemia and hyperglycemia; monitoring blood-glucose levels; dosage adjustments in patients with diabetes, insulin requirements and patients with acromegaly who have moderate or severe hepatic impairment; decrease in thyroid function and intestinal absorption of co-administered drugs; gallstone formation resulting in cholecystitis, cholangitis, and pancreatitis requiring cholecystectomy; angioedema and anaphylaxis; monitoring and laboratory tests may be required; teratogenic risk in pregnant and nursing women; fertility reduction in females
• Conditions of clinical use, adverse reactions, drug interactions, and dosing information

The Product Monograph is also available by calling our medical department at 1-800-982-0340.